Overview
Sponsor-declared trial summary
Phase
Human pharmacology (Phase I) - First administration to humans
Status
Ended
Participants planned
47
Countries
1
Sites
4
Solid Tumors
Key facts
- Sponsor
- iTeos Belgium
- Participant type
- Patients
- Age range
- 18-64 years, 65+ years
- Gender
- Male and Female
- Therapeutic area
- Phenomena and Processes [G] - Cell Physiological Phenomena [G04]
- Trial duration
- completed 9 Jul 2025
- Decision date (initial)
- 2025-04-01
- Transition trial
- No
- Low-intervention
- No
- Rare-disease indication
- No
- Vulnerable population
- No
Trial design
CTIS Part I — objectives, methods, condition coding
Conditions and MedDRA coding
Solid Tumors
| Version | Level | Code | Term | System organ class |
|---|---|---|---|---|
| 27.1 | PT | 10028980 | Neoplasm | 100000004864 |
Sponsors and contacts
Sponsor organisations, regulatory contacts, third parties
iTeos Belgium
- Sponsor organisation
- iTeos Belgium
- Address
- Rue Des Freres Wright 29/3
- City
- Charleroi
- Postcode
- 6041
- Country
- Belgium
Scientific contact point
- Organisation
- iTeos Belgium
- Contact name
- Catherine Hoofd
Public contact point
- Organisation
- iTeos Belgium
- Contact name
- Catherine Hoofd
Locations
1 EU/EEA country · 4 investigational sites
By country
| Country | MS status | Planned subjects | Sites |
|---|---|---|---|
| Belgium | Ended | 47 | 4 |
| Rest of world | — | 0 | — |
Investigational sites
Institut Jules Bordet
Oncology, Mijlenmeersstraat 90, 1070, Anderlecht
UZ Leuven
Oncology, Herestraat 49, 3000, Leuven
Universitair Ziekenhuis Gent
Oncology, Corneel Heymanslaan 10, 9000, Gent
Cliniques Universitaires Saint-Luc
Oncology, Hippokrateslaan 10, Batiment 54, Sint-Lambrechts-Woluwe
Application history
1 submissions — initial application plus substantial / non-substantial modifications
| # | Type | Code | Submitted | Reference MS | Conclusion | Decision date |
|---|---|---|---|---|---|---|
| 1 | INITIAL | IN | 2025-02-06 | Belgium | Acceptable 2025-04-01
|
2025-04-01 |